Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-04-26
2011-04-26
Moore, Susanna (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S081000, C514S210210, C514S217060, C544S280000, C544S244000, C544S250000, C540S600000
Reexamination Certificate
active
07932259
ABSTRACT:
An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
REFERENCES:
patent: 6187781 (2001-02-01), Nakazato et al.
patent: 6600038 (2003-07-01), Nakazato et al.
patent: 2007/0060602 (2007-03-01), Nakazato et al.
patent: 0691128 (1996-01-01), None
patent: 94/13676 (1994-06-01), None
patent: 95/34563 (1995-12-01), None
patent: 0202549 (2002-01-01), None
Vippagunta et. al. (Adv. Drug Delivery Rev., 2001, 48, pp. 3-26).
Hsin, et al., “CRHR1Receptor Binding and Lipophilicity of Pyrrolopyrimidines, Potential Nonpeptide Corticotropin-Releasing Hormone Type 1 Receptor Antagonists”, Bioorganic & Medicinal Chemistry, 2001, 10(1): 175-183.
Hsin, et al., “Synthesis and Biological Activity of Fluoro-Substitutes Pyrrolo[2,3—d]pyrimidines: The Develpment of Potential Positron Emission Tmography Imaging Agents for the Corticotropin-Releasing Hormone Type 1 Receptor”, Biorganic and Medical Chemistry Letters, 2000, 10(8): 707-710.
Bongartz Jean-Pierre A. M.
De Bruyn Marcel F. L.
Hendrickx Robert J. M.
Kennis Ludo E. J.
Luyckx Marcel G. M.
Moore Susanna
Sughrue & Mion, PLLC
Taisho Pharmaceutical Co. Ltd.
LandOfFree
Pyrrolo[2,3-d]pyrimidine derivatives substituted with a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolo[2,3-d]pyrimidine derivatives substituted with a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolo[2,3-d]pyrimidine derivatives substituted with a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2731056